Search

everythinglearnresearchcommunity

for

Search:↓

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

The user experienced significant hair regrowth and improved hair quality after six months of using oral minoxidil, finasteride, and micro-needling. They reported increased libido initially but no other side effects, and they plan to continue the treatment.

A user's 6-month update on their hair loss treatment regimen, which includes finasteride, minoxidil and derma rolling, with no significant side effects.

The user has been using finasteride for six months to address hair loss and is considering adding minoxidil to improve hair thickness. They are also using microneedling, peppermint oil, saw palmetto, biotin, and vitamin D supplements.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

A user's 6 month hairline results from using dutasteride and microneedling, which resulted in successful regrowth of their thinning temples. Other users commented with similar experiences that were also achieved through the use of finasteride, dutasteride and minoxidil.

The conversation is about someone's six-month hair transplant outcome, with a user suggesting the use of finasteride and minoxidil to improve hair growth. Another user commented on the poor condition of the donor hair area.

A user experienced hair regrowth after 6 months on finasteride, which is earlier than the usual 12-18 months observed by their dermatologist. The dermatologist noted this as an exceptionally good response.

The user has been on oral finasteride and minoxidil for six months without seeing hair loss stabilization and has started taking dutasteride twice a week. Other users shared their experiences with hair loss treatments, with one suggesting dutasteride might be more effective than finasteride.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

The user has been using oral finasteride, topical minoxidil, and tretinoin cream for hair loss, with positive progress noted after six months. They are advised to continue their current regimen and consider additional treatments like derma rolling, while being cautious about switching to dutasteride due to potential side effects.

The user is using a hair regrowth protocol including dutasteride, topical and oral minoxidil, dermarolling, ketoconazole shampoo, and tretinoin, but is experiencing slow progress and seeks advice for faster regrowth. Suggestions include quitting smoking, adjusting the regimen, and considering additional treatments like topical finasteride or RU58841.

A user shared a 6-month hair loss progress update using 1 mg finasteride, plans to start minoxidil and RU58841 due to severe shedding, and seeks advice. Others suggest maintaining treatment, switching to different medications, and considering more aggressive treatments due to strong genetic predisposition to baldness.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

A user experienced significant hair improvement using oral finasteride for six months, adding microneedling and switching to non-sulfate shampoo. They managed side effects by working out and noticed no negative impact on libido.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

A user's successful 6-month journey with Minoxidil, Finasteride and 0.05 Derma Rolling to regain their hairline, eyebrows, facial hair and overall youthful look. They also discussed the use of topical minoxidil for eyebrow thickening, as well as other skincare routines and healthy lifestyle habits.

The user reports positive hair regrowth after 6 months using finasteride, minoxidil, occasional derma rolling, and weekly ketoconazole shampoo. Other users encourage the progress and share their own experiences with finasteride.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.